Authors:Péter Feiszt, György Schneider, and Levente Emődy
potential to trigger resistance development [ 7 ]. For these reasons, it is now a subject of pharmaceuticaldevelopments addressing broader therapeutic fields, including nasal MRSA decolonization.
Neither the effect of primycin against non
inflammation [ 95 ]. Due to these activities, peptide Pep19-2.5 was suggested to have a potential for pharmaceuticaldevelopment as a broad-spectrum anti-inflammatory agent in sepsis-induced myocardial inflammation and dysfunction. Moreover, ibuprofen